{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:12:26Z","timestamp":1793301146744,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s40263-016-0391-y","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T13:31:19Z","timestamp":1478611879000},"page":"75-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-9741","authenticated-orcid":false,"given":"Susanna","family":"Every-Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete M.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Nowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Huthwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"391_CR1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2015.05.025","volume":"166","author":"T Baptista","year":"2015","unstructured":"Baptista T, Carrizo E, Fernandez E, Connell L, Servigna M, Parra A, et al. Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics. Schizophr Res. 2015;166:4.","journal-title":"Schizophr Res."},{"key":"391_CR2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ebiom.2016.02.020","volume":"5","author":"S Every-Palmer","year":"2016","unstructured":"Every-Palmer S, Nowitz M, Stanley J, Grant E, Mark H, Dunn H, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016;5:125\u201334.","journal-title":"EBioMedicine."},{"issue":"2","key":"391_CR3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/JCP.0b013e31819a91f1","volume":"29","author":"M Ozbilen","year":"2009","unstructured":"Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol. 2009;29(2):141\u20136.","journal-title":"J Clin Psychopharmacol."},{"issue":"5","key":"391_CR4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","volume":"69","author":"SE Palmer","year":"2008","unstructured":"Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759\u201368.","journal-title":"J Clin Psychiatry."},{"issue":"6","key":"391_CR5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/ijms17060863","volume":"17","author":"A Shirazi","year":"2016","unstructured":"Shirazi A, Stubbs B, Gomez L, Moore S, Gaughran F, Flanagan RJ, et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci. 2016;17(6):863.","journal-title":"Int J Mol Sci."},{"issue":"10","key":"391_CR6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4088\/JCP.11r06977","volume":"73","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307\u201312.","journal-title":"J Clin Psychiatry."},{"key":"391_CR7","doi-asserted-by":"crossref","unstructured":"Every\u2010Palmer S, Newton\u2010Howes G, Clarke MJ. Pharmacological treatment for antipsychotic\u2010related constipation. Cochrane Database Syst Rev. 2014;(5):CD011128.","DOI":"10.1002\/14651858.CD011128"},{"issue":"1","key":"391_CR8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2982.2006.00835.x","volume":"19","author":"A Wald","year":"2007","unstructured":"Wald A. Chronic constipation: advances in management. Neurogastroenterol Motil. 2007;19(1):4\u201310.","journal-title":"Neurogastroenterol Motil."},{"key":"391_CR9","unstructured":"Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. Great Britain: Wiley-Blackwell; 2015."},{"issue":"5","key":"391_CR10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/JCP.0b013e3182a1160d","volume":"33","author":"CE Poetter","year":"2013","unstructured":"Poetter CE, Stewart JT. Treatment of clozapine-induced constipation with bethanechol. J Clin Psychopharmacol. 2013;33(5):713\u20134.","journal-title":"J Clin Psychopharmacol."},{"issue":"1","key":"391_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/acps.12259","volume":"130","author":"J Meyer","year":"2014","unstructured":"Meyer J, Cummings M. Lubiprostone for treatment-resistant constipation associated with clozapine use. Acta Psychiatr Scand. 2014;130(1):71\u20132.","journal-title":"Acta Psychiatr Scand."},{"issue":"2","key":"391_CR12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jpainsymman.2011.12.002","volume":"43","author":"R Twycross","year":"2012","unstructured":"Twycross R, Sykes N, Mihalyo M, Wilcock A. Stimulant laxatives and opioid-induced constipation. J Pain Symptom Manag. 2012;43(2):306\u201313.","journal-title":"J Pain Symptom Manag."},{"key":"391_CR13","doi-asserted-by":"crossref","unstructured":"Yuan C-S (ed). Handbook of opioid bowel syndrome. Binghamton, New York:\u00a0Haworth Medical\u00a0Press; 2005.","DOI":"10.1201\/9781482289633"},{"key":"391_CR14","unstructured":"Goodheart CR, Leavitt SB. Managing opioid-induced constipation in ambulatory-care patients. Pain Treat Topics. 2006:1\u20139."},{"key":"391_CR15","doi-asserted-by":"crossref","unstructured":"Lee\u2010Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570.","DOI":"10.1002\/14651858.CD007570.pub2"},{"issue":"1","key":"391_CR16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2012.10.028","volume":"144","author":"AE Bharucha","year":"2013","unstructured":"Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218.","journal-title":"Gastroenterology."},{"key":"391_CR17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2045125315591917","volume":"5","author":"L Bailey","year":"2015","unstructured":"Bailey L, Varma S, Ahmad N, Gee S, Taylor DM. Factors predicting use of laxatives in outpatients stabilized on clozapine. Ther Adv Psychopharmacol. 2015;5:7.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"8","key":"391_CR18","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/BF02087913","volume":"41","author":"E Corazziari","year":"1996","unstructured":"Corazziari E, Badiali D, Habib F, Reboa G, Pitto G, Mazzacca G, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci. 1996;41(8):1636\u201342.","journal-title":"Dig Dis Sci."},{"issue":"8","key":"391_CR19","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1440-1746.2006.04543.x","volume":"22","author":"K Harish","year":"2007","unstructured":"Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007;22(8):1183\u20139.","journal-title":"J Gastroenterol Hepatol."},{"issue":"4","key":"391_CR20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1365-2036.2002.01210.x","volume":"16","author":"C Sloots","year":"2002","unstructured":"Sloots C, Poen A, Kerstens R, Stevens M, De Pauw M, Van Oene J, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16(4):759\u201367.","journal-title":"Aliment Pharmacol Ther."},{"key":"391_CR21","unstructured":"Every-Palmer S. Research protocol: comparing gastrointestinal motility in clozapine-treated patients before and after laxative treatment. University of Otago Research Archive; 2014. Available at: http:\/\/hdl.handle.net\/10523\/6392 . Accessed 17 Aug 2016."},{"issue":"1","key":"391_CR22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5056\/jnm.2012.18.1.94","volume":"18","author":"ER Kim","year":"2012","unstructured":"Kim ER, Rhee P-L. How to interpret a functional or motility test-colon transit study. J Neurogastroenterol Motil. 2012;18(1):94\u20139.","journal-title":"J Neurogastroenterol Motil."},{"issue":"1","key":"391_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0016-5085(87)90837-7","volume":"92","author":"AM Metcalf","year":"1987","unstructured":"Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterology. 1987;92(1):40\u20137.","journal-title":"Gastroenterology."},{"issue":"2","key":"391_CR24","doi-asserted-by":"crossref","first-page":"W56","DOI":"10.2214\/AJR.07.2278","volume":"189","author":"F Pomerri","year":"2007","unstructured":"Pomerri F, Frigo AC, Grigoletto F, Dodi G, Muzzio PC. Error count of radiopaque markers in colonic segmental transit time study. Am J Roentgenol. 2007;189(2):W56\u20139.","journal-title":"Am J Roentgenol."},{"issue":"8","key":"391_CR25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/BF02050328","volume":"35","author":"M Bouchoucha","year":"1992","unstructured":"Bouchoucha M, Devroede G, Arhan P, Strom B, Weber J, Cugnenc P-H, et al. What is the meaning of colorectal transit time measurement? Dis Colon Rectum. 1992;35(8):773\u201382.","journal-title":"Dis Colon Rectum."},{"issue":"2","key":"391_CR26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/ajg.2009.612","volume":"105","author":"RJ Saad","year":"2010","unstructured":"Saad RJ, Rao SS, Koch KL, Kuo B, Parkman HP, McCallum RW, et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol. 2010;105(2):403\u201311.","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"391_CR27","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","volume":"130","author":"GF Longstreth","year":"2006","unstructured":"Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480\u201391.","journal-title":"Gastroenterology."},{"issue":"2","key":"391_CR28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.schres.2004.05.015","volume":"73","author":"J Hennen","year":"2005","unstructured":"Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005;73(2):139\u201345.","journal-title":"Schizophr Res."},{"issue":"2","key":"391_CR29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/ajp.152.2.183","volume":"152","author":"H Meltzer","year":"1995","unstructured":"Meltzer H, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152(2):183.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"391_CR30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00001648-199710000-00010","volume":"8","author":"A Walker","year":"1997","unstructured":"Walker A, Lanza L, Arellano F, Rothman K. Mortality in current and former users of clozapine. Epidemiology. 1997;8(6):671.","journal-title":"Epidemiology."},{"key":"391_CR31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1192\/bjp.175.6.576","volume":"175","author":"J Munro","year":"1999","unstructured":"Munro J, O\u2019Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576.","journal-title":"Br J Psychiatry."},{"issue":"3","key":"391_CR32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/schbul\/sbu120","volume":"41","author":"RD Hayes","year":"2015","unstructured":"Hayes RD, Downs J, Chang C-K, Jackson RG, Shetty H, Broadbent M, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2015;41(3):644.","journal-title":"Schizophr Bull."},{"issue":"9690","key":"391_CR33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, L\u00f6nnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620\u20137.","journal-title":"Lancet."},{"issue":"2","key":"391_CR34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","volume":"173","author":"T Stroup","year":"2016","unstructured":"Stroup T, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173(2):166.","journal-title":"Am J Psychiatry."},{"issue":"9","key":"391_CR35","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1017\/S146114571100201X","volume":"15","author":"C Frogley","year":"2012","unstructured":"Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine\u2019s anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15(9):1351\u201371.","journal-title":"Int J Neuropsychopharmacol."},{"issue":"1","key":"391_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","volume":"14","author":"HY Meltzer","year":"1997","unstructured":"Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997;14(1):1\u201320.","journal-title":"Curr Med Res Opin."},{"issue":"12","key":"391_CR37","first-page":"1049","volume":"19","author":"N Sepp\u00e4l\u00e4","year":"2004","unstructured":"Sepp\u00e4l\u00e4 N, Kovio C, Leinonen E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs. 2004;19(12):1049\u201355.","journal-title":"CNS Drugs."},{"issue":"8","key":"391_CR38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0269881108093588","volume":"23","author":"A Wheeler","year":"2009","unstructured":"Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol. 2009;23(8):957.","journal-title":"J Psychopharmacol."},{"issue":"7","key":"391_CR39","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4088\/JCP.v68n0708","volume":"68","author":"J Atkinson","year":"2007","unstructured":"Atkinson J, Douglas-Hall P, Fischetti C, Sparshatt A, Taylor D. Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry. 2007;68(7):1027.","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"391_CR40","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ije\/dym087","volume":"36","author":"J Pildal","year":"2007","unstructured":"Pildal J, Hrobjartsson A, J\u00f8rgensen K, Hilden J, Altman D, G\u00f8tzsche P. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007;36(4):847\u201357.","journal-title":"Int J Epidemiol."},{"issue":"7644","key":"391_CR41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","volume":"336","author":"L Wood","year":"2008","unstructured":"Wood L, Egger M, Gluud LL, Schulz KF, J\u00fcni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601\u20135.","journal-title":"BMJ."},{"issue":"4","key":"391_CR42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/10398560802189896","volume":"16","author":"A McKean","year":"2008","unstructured":"McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring clozapine in Christchurch. Australas Psychiatry. 2008;16(4):263\u20137.","journal-title":"Australas Psychiatry."},{"issue":"6","key":"391_CR43","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1345\/aph.1K662","volume":"42","author":"AJ Wheeler","year":"2008","unstructured":"Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother. 2008;42(6):852\u201360.","journal-title":"Ann Pharmacother."},{"issue":"11","key":"391_CR44","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/j.pain.0000000000000304","volume":"156","author":"B Stubbs","year":"2015","unstructured":"Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaughran F, Correll C. Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain. 2015;156(11):2121.","journal-title":"Pain."},{"issue":"1","key":"391_CR45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archsurg.1988.01400250059010","volume":"123","author":"LK Bickerstaff","year":"1988","unstructured":"Bickerstaff LK, Harris SC, Leggett RS, Cheah K-C. Pain insensitivity in schizophrenic patients: a surgical dilemma. Arch Surg. 1988;123(1):49\u201351.","journal-title":"Arch Surg."},{"issue":"5","key":"391_CR46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004836-200305000-00004","volume":"36","author":"A Wald","year":"2003","unstructured":"Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol. 2003;36(5):386\u20139.","journal-title":"J Clin Gastroenterol."},{"issue":"1","key":"391_CR47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1572-0241.2005.40885.x","volume":"100","author":"SA M\u00fcller-Lissner","year":"2005","unstructured":"M\u00fcller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100(1):232\u201342.","journal-title":"Am J Gastroenterol."},{"issue":"1\u20133","key":"391_CR48","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.forsciint.2010.07.021","volume":"206","author":"RJ Flanagan","year":"2011","unstructured":"Flanagan RJ, Ball RY. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci Int. 2011;206(1\u20133):e31\u20136.","journal-title":"Forensic Sci Int."},{"key":"391_CR49","unstructured":"Every-Palmer S. The Porirua Protocol: guidance to prevent clozapine-related constipation (version 1). University of Otago Research Archive. Available at: http:\/\/hdl.handle.net\/10523\/6763 . Accessed 17 Aug 2016."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0391-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0391-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0391-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T05:35:15Z","timestamp":1601184915000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0391-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0391-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]}}}